Valuation: Stoke Therapeutics, Inc.

Market Cap 1.82B 1.6B 1.49B 1.37B 2.57B 176B 2.61B 17.7B 6.92B 86.4B 6.85B 6.7B 299B P/E 2026 *
-8.92x
P/E 2027 * -9.25x
Enterprise Value 1.63B 1.43B 1.33B 1.22B 2.3B 157B 2.33B 15.81B 6.18B 77.19B 6.12B 5.99B 267B EV / Sales 2026 *
67x
EV / Sales 2027 * 33.7x
Free-Float
96.18%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week+0.86%
Current month-10.45%
1 month-3.62%
3 months-13.90%
6 months-0.54%
Current year-7.69%
1 week 27.24
Extreme 27.235
30.3
1 month 27.24
Extreme 27.235
33.72
Current year 25.21
Extreme 25.21
40.22
1 year 12.25
Extreme 12.25
40.22
3 years 3.35
Extreme 3.35
40.22
5 years 3.35
Extreme 3.35
40.22
10 years 3.35
Extreme 3.35
71.58
Manager TitleAgeSince
Chief Executive Officer 60 2025-03-18
Chief Tech/Sci/R&D Officer 54 2014-05-31
Director of Finance/CFO 49 2024-05-06
Director TitleAgeSince
Director/Board Member 72 2015-08-31
Director/Board Member 76 2017-09-30
Chairman 65 2015-06-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Don

Director

-303,190 0.5126%
7/15/26 Free

Chief Technology Officer

225,000 0.3804%
7/1/26 Sell

Chief Technology Officer

-7,228 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%+0.86%+123.66%+352.86% 1.82B
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average +0.08%+0.83%+62.24%+133.82% 24.71B
Weighted average by Cap. +0.47%+0.91%+74.81%+137.99%

Financials

2026 *2027 *
Net sales 24.32M 21.36M 19.86M 18.23M 34.25M 2.34B 34.77M 236M 92.15M 1.15B 91.29M 89.32M 3.98B 46.5M 40.84M 37.98M 34.86M 65.49M 4.48B 66.5M 451M 176M 2.2B 175M 171M 7.61B
Net income -211M -185M -172M -158M -297M -20.29B -301M -2.04B -799M -9.98B -791M -774M -34.49B -212M -186M -173M -159M -299M -20.43B -303M -2.06B -804M -10.04B -796M -779M -34.72B
Net Debt -194M -171M -159M -146M -274M -18.72B -278M -1.89B -737M -9.2B -730M -714M -31.82B -256M -225M -209M -192M -361M -24.67B -366M -2.48B -971M -12.13B -962M -941M -41.93B
Logo Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Employees
170
Date Price Change Volume
26-07-24 US$29.30 -1.18% 441,847
26-07-23 US$29.65 +2.38% 669,437
26-07-22 US$28.96 +0.52% 416,625
26-07-21 US$28.81 +4.08% 604,488
26-07-20 US$27.68 -4.72% 546,520
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
29.30USD
Average target price
45.82USD
Spread / Average Target
+56.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STOK Stock